Technical Analysis for PMN - ProMIS Neurosciences Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.92 | 1.24% | 0.02 |
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | 1.24% | |
| Fell Below 200 DMA | Bearish | 1.24% | |
| Fell Below 50 DMA | Bearish | 1.24% | |
| 20 DMA Resistance | Bearish | -6.11% | |
| Crossed Above 50 DMA | Bullish | -6.11% | |
| Wide Bands | Range Expansion | -6.11% | |
| 50 DMA Resistance | Bearish | -1.81% | |
| 200 DMA Support | Bullish | -1.81% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| 200 DMA Resistance | about 20 hours ago |
| Possible NR7 | about 22 hours ago |
| Possible Inside Day | about 22 hours ago |
| 60 Minute Opening Range Breakout | about 24 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
ProMIS Neurosciences Inc. Description
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Disease Alzheimer's Disease Parkinson's Disease Neurological Disorders Dementia Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Lewy Body Dementia Treatment Of Neurodegenerative Diseases Multiple System Atrophy Neurodegenerative Disease Neuropathology Alpha Synuclein
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8 |
| 52 Week Low | 0.9506 |
| Average Volume | 15,582 |
| 200-Day Moving Average | 1.90 |
| 50-Day Moving Average | 2.04 |
| 20-Day Moving Average | 2.02 |
| 10-Day Moving Average | 1.97 |
| Average True Range | 0.21 |
| RSI (14) | 45.65 |
| ADX | 18.11 |
| +DI | 16.56 |
| -DI | 27.45 |
| Chandelier Exit (Long, 3 ATRs) | 1.99 |
| Chandelier Exit (Short, 3 ATRs) | 2.02 |
| Upper Bollinger Bands | 2.27 |
| Lower Bollinger Band | 1.77 |
| Percent B (%b) | 0.31 |
| BandWidth | 24.97 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0105 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.00 | ||||
| Resistance 3 (R3) | 2.00 | 1.97 | 1.99 | ||
| Resistance 2 (R2) | 1.97 | 1.96 | 1.97 | 1.98 | |
| Resistance 1 (R1) | 1.95 | 1.94 | 1.96 | 1.95 | 1.98 |
| Pivot Point | 1.92 | 1.92 | 1.93 | 1.92 | 1.92 |
| Support 1 (S1) | 1.90 | 1.91 | 1.91 | 1.90 | 1.87 |
| Support 2 (S2) | 1.87 | 1.89 | 1.87 | 1.87 | |
| Support 3 (S3) | 1.85 | 1.87 | 1.86 | ||
| Support 4 (S4) | 1.85 |
